ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

8 links3 made here, not in the record12 judgments2 judges (the rules as one: Rule based)0 record changes seen
Claude Opus 5.5Rule basedMade here
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07782840QL1706 Plus NeoadjuvantEndocrine Therapy inHR-Positive/HER2-NegativeBreast Cancer With a PoorResponse to NeoadjuvantChemotherapyHebei Medical University FourtPhase 2 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›No new version seen since tracking began Sep 25, 2026.CONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSIparomlimab/TuvonralimabEntry “Iparomlimab and Tuvonralimab (…›Nov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAromatase inhibitorsEntry “Aromatase Inhibitor (AI)”, rea…›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAbemaciclibEntry “CDK4/6 inhibitor”, read by our…›Nov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionGoserelinEntry “Ovarian function suppression”,…›Nov 10 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundRibociclibMade here · Found by reading; no entr…›Nov 3 · Claude Opus 5.5 · Background · partnerBackground · partnerAnastrozoleMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · Background · optionBackground · optionExemestaneMade here · Found by reading; no entr…›Nov 10 · Claude Opus 5.5 · Background · optionBackground · option

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Iparomlimab/Tuvonralimab

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Iparomlimab and Tuvonralimab (QL1706)”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 3Ribociclibmade hereClaude Opus 5.5Background · partnerCurrent
Nov 10Iparomlimab/TuvonralimabClaude Opus 5.5TestedCurrent
Nov 10Aromatase inhibitorsClaude Opus 5.5BackgroundCurrent
Nov 10AbemaciclibClaude Opus 5.5Background · optionCurrent
Nov 10GoserelinClaude Opus 5.5BackgroundCurrent
Nov 10Anastrozolemade hereClaude Opus 5.5Background · optionCurrent
Nov 10Exemestanemade hereClaude Opus 5.5Background · optionCurrent
Nov 18Iparomlimab/TuvonralimabRule based · role ruleTestedAgrees
Nov 18Aromatase inhibitorsRule based · role ruleBackgroundAgrees
Nov 18AbemaciclibRule based · role ruleBackgroundAgrees
Nov 18GoserelinRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.